We are live on ! Find out more
GBT

Global Blood Therapeutics, Inc.
GBT

Delisted

GBT was delisted on the 4th of October, 2022.

Back to rankings

196 hedge funds and large institutions have $2.35B invested in Global Blood Therapeutics, Inc. in 2018 Q2 according to their latest regulatory filings, with 44 funds opening new positions, 86 increasing their positions, 48 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

106% more call options, than puts

Call options by funds: $180M | Put options by funds: $87.2M

91% more first-time investments, than exits

New positions opened: 44 | Existing positions closed: 23

79% more repeat investments, than reductions

Existing positions increased: 86 | Existing positions reduced: 48

17% more funds holding in top 10

Funds holding in top 10: 6 → 7 (+1)

11% more funds holding

Funds holding: 176 → 196 (+20)

3% less capital invested

Capital invested by funds: $2.41B → $2.35B (-$61.8M)

Holders
196
Holders Change
+20
Holders Change %
+11.36%
% of All Funds
4.49%
Holding in Top 10
7
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+16.67%
% of All Funds
0.16%
New
44
Increased
86
Reduced
48
Closed
23
Calls
$180M
Puts
$87.2M
Net Calls
+$92.5M
Net Calls Change
+$68.4M

Top Buyers

1
FCM
Farallon Capital Management
California
+$54M
2
CCM
Camber Capital Management
Massachusetts
+$45.5M
3
BlackRock
BlackRock
New York
+$40.9M
4
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$20.6M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
+$19.8M

Top Sellers

1
ACA
Avoro Capital Advisors
New York
-$48.5M
2
O
OrbiMed
New York
-$46.4M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$34.9M
4
Deutsche Bank
Deutsche Bank
Germany
-$24.5M
5
RI
RTW Investments
New York
-$22.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$292M -$34.9M -767,345 -11%
PA
2
Perceptive Advisors
New York
$218M -$7.29M -160,156 -3%
Janus Henderson Group
3
Janus Henderson Group
United Kingdom
$188M +$20.6M +452,843 +12%
BlackRock
4
BlackRock
New York
$187M +$40.9M +898,162 +28%
Vanguard Group
5
Vanguard Group
Pennsylvania
$185M +$10.5M +231,569 +6%
Wellington Management Group
6
Wellington Management Group
Massachusetts
$182M -$14.8M -324,768 -7%
T. Rowe Price Associates
7
T. Rowe Price Associates
Maryland
$124M +$9.76M +214,308 +8%
State Street
8
State Street
Massachusetts
$109M +$17M +373,768 +18%
CCM
9
Camber Capital Management
Massachusetts
$99.4M +$45.5M +1,000,000 +83%
FCM
10
Farallon Capital Management
California
$53.6M +$54M +1,185,000 New
GPP
11
Great Point Partners
Connecticut
$34.8M +$1.54M +33,769 +5%
Franklin Resources
12
Franklin Resources
California
$33.4M +$5.37M +118,029 +19%
ACA
13
Avoro Capital Advisors
New York
$31.7M -$48.5M -1,065,000 -60%
Northern Trust
14
Northern Trust
Illinois
$27.2M +$5.51M +121,043 +25%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$22.9M +$3.93M +86,358 +21%
CC
16
Casdin Capital
New York
$21.7M -$5.46M -120,000 -20%
O
17
OrbiMed
New York
$20.2M -$46.4M -1,019,255 -70%
Point72 Asset Management
18
Point72 Asset Management
Connecticut
$19.7M +$19.8M +435,900 New
Goldman Sachs
19
Goldman Sachs
New York
$19.2M +$1.01M +22,153 +5%
PAMU
20
Pictet Asset Management (UK)
United Kingdom
$18.9M +$4.71M +103,353 +33%
NC
21
Nexthera Capital
New York
$18.3M +$4.05M +88,945 +28%
Millennium Management
22
Millennium Management
New York
$16.5M +$10.7M +234,851 +181%
FIM
23
Fernwood Investment Management
Massachusetts
$16.1M +$25.5K +560 +0.2%
Loomis, Sayles & Company
24
Loomis, Sayles & Company
Massachusetts
$14.8M +$1.45M +31,743 +11%
TA
25
Teachers Advisors
New York
$14.6M +$1.04M +22,765 +8%
1
2 3 4 5

GBT Hedge Fund Activity: Q2 2018 in Review

196 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Global Blood Therapeutics, Inc. (GBT) for Q2 2018, worth a combined $2.35B — down 2.6% from $2.41B a quarter earlier.

Buyers outnumbered sellers: 44 funds opened new GBT positions and 23 closed out — a net gain of 21 holders — while 86 added to existing stakes and 48 trimmed.

The largest buyer was Farallon Capital Management, opening a new position worth an estimated $54M. The largest seller was Avoro Capital Advisors, cutting an estimated $48.5M.

  • 196 institutional investors held Global Blood Therapeutics, Inc. (GBT) as of Q2 2018, up from 176 in Q1 2018.
  • Funds reported $2.35B of Global Blood Therapeutics, Inc. stock for Q2 2018, down 2.6% quarter-over-quarter.
  • 44 funds opened new Global Blood Therapeutics, Inc. positions in Q2 2018 and 23 closed out, a net change of +21 holders.
  • The largest Global Blood Therapeutics, Inc. buyer in Q2 2018 was Farallon Capital Management, an estimated $54M added.
  • The largest Global Blood Therapeutics, Inc. seller in Q2 2018 was Avoro Capital Advisors, an estimated $48.5M sold.

Based on aggregated 13F filings for Q2 2018.